Ruben Yu
Psychiatric/Mental Health · Gardena, CANPI 1205289337
Payments from drug & device makers
Across 11 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$97
- Neurocrine Biosciences, Inc.$62
- Mckesson Medical-surgical Minnesota Supply, Inc$30
- Takeda Pharmaceuticals U.S.A., Inc.$25
- Otsuka America Pharmaceutical, Inc.$21
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$17
- plus $31 from 2 others
What the payments were for
- Food & beverage$282100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 3 | $97 |
| Neurocrine Biosciences, Inc. | 2 | $62 |
| Mckesson Medical-surgical Minnesota Supply, Inc | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
How this compares
$282 in reported general payments places this provider in the 40th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 12 | $18,488 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 45 | $6,469 |
| Aripiprazole | 63 | $5,269 |
| Olanzapine | 111 | $3,322 |
| Quetiapine Fumarate | 108 | $2,825 |
| Divalproex Sodium | 21 | $2,314 |
| Oxcarbazepine | 53 | $2,272 |
| Risperidone | 83 | $1,575 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 19 | $1,223 |
| Benztropine Mesylate | 54 | $579 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 22 | $525 |
| Sertraline Hcl | 65 | $516 |
| Lorazepam | 54 | $480 |
| Fluoxetine Hcl | 60 | $415 |
| Gabapentin | 26 | $412 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Gardena
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- David OhIrvine$72K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.